Valerian Root for Sleep: What the Evidence Shows

Verdict: Weak. Many trials, inconsistent results, and no clear signal in meta-analyses. The evidence does not support a confident recommendation.

The claim: valerian root promotes relaxation and improves sleep quality naturally. It has been sold on this basis for longer than most supplements on the shelf, with use documented since ancient Greece. Hippocrates noted its properties. Galen prescribed it for insomnia in the second century. More time in market has meant more trials. More trials have not meant a clearer answer.

The claim inventory

The marketing for valerian tends to lean on two arguments: tradition and mechanism. The tradition argument is that valerian has been used for sleep for over two thousand years. This is true, and it proves nothing about efficacy. Many traditional remedies do not survive controlled testing. The mechanism argument is that valerian acts on GABA receptors, the same system targeted by benzodiazepines. This is partially true, partially oversimplified, and does not establish clinical efficacy at the doses available in supplements.

The mechanism

Valerian (Valeriana officinalis) is thought to act on GABA-A receptors, and some in vitro studies suggest that valerenic acid, one of several active compounds in the root, may inhibit GABA reuptake and enhance GABAergic signaling. Other potentially active constituents include iridoids (valepotriates) and sesquiterpenes. The mechanism is plausible in the sense that GABA is central to sleep initiation, but the specific binding characteristics of valerian’s active compounds and their bioavailability after oral administration remain poorly defined.

The comparison to benzodiazepines, sometimes implicit in supplement marketing, is misleading. Benzodiazepines are potent, selective GABA-A receptor agonists with well-characterized dose-response curves. Valerian is a complex plant extract with multiple constituents, uncertain bioavailability, and weak receptor affinity compared to pharmaceutical GABA-active compounds. Sharing a receptor family does not mean sharing an effect size.

What the trials show

Valerian has been studied in at least 16 RCTs, an unusually large number for an herbal sleep supplement. The volume of research would normally produce clarity. Here it has not, and the reasons are instructive.

The Bent meta-analysis pooled 16 RCTs with 1,093 participants and found a dichotomous improvement in subjective sleep quality (OR 1.37, 95% CI 1.05-1.78) but no improvement in objective measures including polysomnography [2]. The effect was statistically significant but small, and it was limited to subjective reports. When participants were asked whether they thought their sleep improved, slightly more said yes in the valerian group. When their sleep was measured objectively, no difference appeared.

The Fernandez-San-Martin meta-analysis of 18 RCTs reached a similar ambivalent conclusion: valerian “might” improve subjective sleep quality, but the evidence was not convincing due to heterogeneity in preparations, doses, duration, and outcome measures [1]. The word “might” in a meta-analytic conclusion is not encouraging.

On the negative side, the two most methodologically rigorous trials found no effect. The Oxman trial, one of the largest at 405 participants, compared valerian to placebo over two weeks and found no significant difference in any sleep measure [5]. The trial was notable for its size and for its pragmatic design. The Taibi trial specifically enrolled older women with insomnia, a population where many supplements show their best results, and also found no effect [4]. When the largest and best-designed trials are negative, the positive signal from smaller trials warrants skepticism.

The preparation problem

One reason for the inconsistency may be that “valerian” is not one product. Different trials used different preparations: aqueous extracts, ethanolic extracts, dried root powder, extracts standardized to different compounds, at different doses (200mg to 900mg), with different extraction solvents and processing methods. What is biologically active in one preparation may not be present, or present in the same concentration, in another.

This is not a trivial objection. Two “valerian” products from different manufacturers may contain different chemical profiles, and a meta-analysis pooling their results is pooling different interventions under the same name. It also means that a consumer choosing a valerian product at a store has no way to know whether the product resembles the one used in any given trial, even a positive one.

The delayed-onset hypothesis

Some proponents argue that valerian requires 2-4 weeks of daily use before sleep effects emerge, which would explain why short trials (many lasted only 14 days) show null results. This is a reasonable hypothesis, but it has not been tested in a properly designed dose-duration study. The longer trials in the literature (4-6 weeks) do not consistently show larger effects than the shorter ones, which weakens the argument. If valerian truly required an accumulation period, you would expect to see a dose-duration relationship in the data. It does not appear.

The hypothesis also creates a practical problem for consumers. A product that requires 2-4 weeks of daily use before producing any effect is difficult to evaluate personally. By four weeks, a placebo response, natural fluctuation in sleep quality, and changes in other life circumstances all contribute to whatever the person experiences. The inability to tell whether valerian is doing anything is not just a clinical trial problem; it is a user experience problem.

Combination products

Most valerian products on store shelves combine valerian with other herbs: hops, lemon balm, passionflower, lavender. The combinations are marketed as synergistic, but the evidence for synergy is absent. A few trials have tested valerian-hops combinations, but the designs do not allow separation of individual ingredient effects. When a combination trial shows a positive result, it is impossible to know whether valerian contributed, the companion herb contributed, or neither contributed beyond placebo.

The combination problem compounds the preparation problem: not only is “valerian” not one product, but the product most consumers actually buy is not even valerian alone. It is valerian plus other ingredients, at varying ratios, with no evidence that the specific combination on the shelf has been tested in any trial.

Where the evidence is stronger

There is no subpopulation where the evidence is convincingly strong. The best that can be said: some individuals in some trials reported improved subjective sleep quality with valerian, and the aggregate signal across all trials leans slightly positive for this subjective measure. The Natural Medicines Comprehensive Database rates valerian as “Possibly Effective,” which is the database’s way of saying the evidence is suggestive but not sufficient [6].

Valerian does have a favorable safety profile, which counts for something in a supplement category where safety data is often sparse. It has been used for centuries without evidence of serious harm at standard doses, and the clinical trials report few adverse effects beyond occasional GI upset and the distinctive smell that some find unpleasant. “Safe but probably not effective” is a defensible summary, and safety is not a trivial attribute when the comparison set includes products with less long-term safety data.

Where the evidence is weaker

Objective sleep measures (polysomnography, actigraphy) consistently show no improvement with valerian [2]. The largest trials show no effect even on subjective measures. The broader herbal medicine review by Leach and Page, which evaluated valerian alongside other herbal sleep aids, concluded that the evidence is insufficient for a clinical recommendation [3].

The subjective-versus-objective split is worth noting. A supplement that improves how people feel about their sleep without changing how they actually sleep could be useful, but it raises the question of whether the effect is pharmacological or expectational. Valerian tea is consumed as a ritual, has a distinctive (and to many, unpleasant) smell, and has a long cultural association with sleep. These are all ingredients for a placebo response.

How it compares to CBT-I

CBT-I produces durable improvement in both subjective and objective sleep measures, with effect sizes that are clinically meaningful: 30-40 minutes reduction in sleep onset latency, significant improvements in sleep efficiency, and remission rates of 70-80% among completers. Valerian, at its best interpretation, produces a small, inconsistent improvement in subjective sleep quality with no objective change. These are not comparable interventions.

The contrast is sharpened by the fact that CBT-I effects persist for years after treatment ends, requiring no ongoing use, while any valerian effect presumably requires continued nightly supplementation. A treatment that stops working when you stop taking it is pharmacologically rational (most medications work this way) but represents a different proposition than a treatment that changes behavior permanently. For someone considering long-term nightly use of a supplement with unclear efficacy, the time and cost of a CBT-I course (typically 6-8 sessions) represents a potentially better investment.

The bottom line

Valerian has been studied more than most herbal sleep supplements and the results remain inconclusive after more than two decades of trials. If the evidence were going to clarify with more data, it probably would have by now. At standard doses, the risk is low: valerian is generally well tolerated, and rare reports of liver toxicity have not been clearly attributed to valerian alone. The expected benefit is also low and inconsistent. “One of the most studied” and “one of the most effective” are different statements, and the distinction is the whole story here.

If you’re struggling with sleep regularly, speak with a GP or pharmacist before adding supplements or medications. For persistent insomnia, AASM guidelines recommend CBT-I as the first-line treatment. The American Academy of Sleep Medicine has a provider finder at sleepeducation.org.